CanSino Biologics Inc. (HKG:6185)
34.72
+0.84 (2.48%)
Mar 10, 2026, 1:15 PM HKT
CanSino Biologics Revenue
In the year 2025, CanSino Biologics had annual revenue of 1.07B CNY with 26.18% growth. CanSino Biologics had revenue of 375.34M in the quarter ending December 31, 2025, with 34.40% growth.
Revenue
1.07B CNY
Revenue Growth
+26.18%
P/S Ratio
11.54
Revenue / Employee
957.76K CNY
Employees
1,115
Market Cap
13.72B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07B | 221.57M | 26.18% |
| Dec 31, 2024 | 846.34M | 489.25M | 137.01% |
| Dec 31, 2023 | 357.08M | -677.51M | -65.49% |
| Dec 31, 2022 | 1.03B | -3.27B | -75.94% |
| Dec 31, 2021 | 4.30B | 4.27B | 17,174.82% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Consun Pharmaceutical Group | 3.58B |
| CF PharmTech | 647.51M |
| Sihuan Pharmaceutical Holdings Group | 2.30B |
| Luye Pharma Group | 6.76B |
| Shandong Xinhua Pharmaceutical Company | 9.28B |
| China Traditional Chinese Medicine Holdings Co. | 17.08B |
| Ab&B Bio-Tech CO., LTD. JS | 354.77M |
| OneRobotics (Shenzhen) | 801.23M |
CanSino Biologics News
- 4 days ago - Meningitis Shot Delivers Dose Of Good Cheer For CanSino - Benzinga
- 4 weeks ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 11 months ago - CanSino Biologics CEO on earnings, business outlook, and international partnerships - CNBC
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire